GSK · story · 22 October – 27 October
GSK · 5 headlines from 2 outlets, from 22 October 2026 to 27 October 2026.
JP Morgan reaffirmed a Sell rating and Jefferies issued a 2,500p target.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
AD HOC NEWS is the largest at 6.9, ahead of MarketScreener (−6.7). MarketScreener is below zero.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| AD HOC NEWS | 6.9 |
| MarketScreener | −6.7 |
| Outlet | Headlines | Average tone |
|---|---|---|
| AD HOC NEWS | 3 | +6.9 |
| MarketScreener | 2 | −6.7 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +7.5 | New product approval alongside analyst price target. |
| −6.7 | Bank maintains negative recommendation on the shares. |
| +5.0 | Broker sets a price target above recent levels. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +8.3 | Jefferies reiterates Buy rating. |
| −6.7 | JP Morgan keeps Sell rating. |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.